Objectives: To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer. Methods: Between 1989 and 2001, 470 patients with rectal cancer were treated with preoperative (89%) or postoperative (11%) chemoradiation and mesorectal excision. Median radiation dose was 45 Gy; 97% received concurrent infusional 5-fluorouracil, and 65% received adjuvant chemotherapy. Median follow-up interval was 5.7 years.
M
ultiple randomized trials have established the role of neoadjuvant and adjuvant radiotherapy and chemotherapy in patients with resected stage T3/T4 or node-positive rectal cancer. [1] [2] [3] [4] However, the risks of relapse and death vary widely among rectal cancer patients. 5 Different treatment strategies may be indicated for different groups of rectal cancer patients, on the basis of their risks for local and distant failure and death. For example, patients at a high risk for DM or death may be candidates for more aggressive adjuvant chemotherapy regimens. Clinical and pathologic factors that predict relapse and death can therefore help in the design of risk-adapted therapy for rectal cancer patients.
The goal of this study was to identify clinical and pathologic factors that predict for locoregional relapse (LR), distant metastasis (DM), and overall survival (OS) in rectal cancer patients. We performed univariate and multivariate analysis to identify predictive factors in 470 patients treated with mesorectal excision and either neoadjuvant or adjuvant chemoradiation at The University of Texas M. D. Anderson Cancer Center, with a median follow-up interval of over 5 years.
PATIENTS AND METHODS
The study included all patients (n ϭ 470) with newly diagnosed rectal cancer (located at Յ12 cm from the anal verge) and no evidence of DM, who were treated with mesorectal excision and either preoperative or postoperative chemoradiation at M. D. Anderson Cancer Center, between September 1989 and December 2001. The hospital and radiotherapy records of these patients were reviewed for this study. The study was approved by the M. D. Anderson Institutional Review Board.
Staging Evaluation
All patients underwent digital rectal examination, chest X-ray, abdominopelvic CT scan, and flexible endoscopy. Selected patients also underwent rigid proctoscopy, based on physician preference. The distance of the inferior aspect of the tumor from the anal verge was determined by rigid proctoscopy, flexible endoscopy, or digital rectal examination. If the findings were discordant, the rigid proctoscopy findings were used to determine distance from the anal verge. Digital rectal examination was used to assess tumor mobility, while rigid proctoscopy and flexible endoscopy were used to evaluate tumor size, obstruction of the lumen, and the percentage of rectal lumen circumference that was involved by tumor. Endoscopic ultrasound was performed in 362 (77%) patients. Clinical stage was based on the findings of endoscopic ultrasound, computed tomography (CT) scan and digital rectal examination. Biopsies and operative pathologic specimens were reviewed by gastrointestinal pathologists at M. D. Anderson, who determined the pathologic stage, tumor pathology, histologic grade, and presence of lymphovascular space invasion and perineural invasion. The American Joint Committee on Cancer TNM system, 5th edition, was used for staging. 6 Patient and tumor characteristics are shown in Table 1 . Patients had a median tumor size of 5 cm (range, 1-15 cm), and the tumors were located at a median distance of 5 cm (range, 0 -12 cm) from the anal verge. The clinical T stage was ՅT2 in 7%, T3 in 78%, T4 in 8%, and unknown in 6% of patients. The clinical nodal stage was N0 in 30%, N1-2 in 53%, and unknown in 16%.
Treatment
Of the 470 patients, 418 (89%) underwent preoperative radiotherapy and 52 (11%) underwent postoperative radiotherapy ( Table 2 ). The median radiation dose was 45 Gy (range, 19.8 -58.6 Gy). In 465 (99%) patients, the pelvis received a dose of 45 Gy in 25 fractions over 5 weeks. In 81 (17%) patients, the dose to the pelvis was accompanied by a boost of 7.5 Gy in 5 fractions, delivered as a second daily fraction in the last week of treatment, taking the cumulative dose to 52.5 Gy. In 52 (11%) patients, the dose to the pelvis was followed sequentially by a boost, for a cumulative dose of 50.4 to 58.6 Gy. Radiation therapy was delivered by 18-MV photons with customized blocking. Most patients (n ϭ 454, 97%) were treated in the prone position, using an open tabletop (belly board) device for bowel exclusion, with a 3-field technique (posterior and 2 lateral fields). All patients underwent mesorectal excision. Low anterior resection was performed in 203 (43%) patients, proctectomy with coloanal anastomosis in 97 (21%), abdominoperineal resection in 147 (31%), pelvic exenteration in 16 (3%), and other procedures in 7 (1%). Only 6 (1%) patients had a positive radial margin. The median number of lymph nodes removed was 6 (range, 0 -62).
Of the 470 patients, 464 (99%) received concurrent chemotherapy with radiotherapy, including infusional 5-fluorouracil (5-FU) in 447 (95%) patients, infusional 5-FU and cisplatin in 8 (2%), and tegafur and uracil in 9 (2%). Adjuvant chemotherapy was administered to 305 (65%) patients. Adjuvant chemotherapy included 5-FU and leucovorin in 224 patients, 5-FU and levamisole in 35 patients, other 5-FUbased regimens in 18 patients, tegafur and uracil in 9 patients, and capecitabine in 5 patients.
Follow-Up
Patients were scheduled for follow-up visits every 3 to 4 months for the first 2 years, every 6 months for up to 5 years, and annually thereafter, with a medical oncologist, surgical oncologist, or radiation oncologist. For most patients, follow-up evaluations included physical examination at each visit, abdomen and pelvic CT scans and chest x-rays every 6 months for the first 2 years and every year thereafter, and colonoscopy every 1 to 3 years. For patients who could not return to M. D. Anderson for follow-up, information was obtained from the patient or the patient's local oncologist by mail or by phone calls. Follow-up information also was obtained from the M. D. Anderson Tumor Registry, which collects information on patients annually through letters, phone calls, and Bureau of Vital Statistics records. The median follow-up interval was 5.7 years (range, 0.3-14.3 years).
Statistical Analysis
OS, freedom from LR, and freedom from DM were estimated by Kaplan-Meier methods. 7 LR was defined as any tumor recurrence in the pelvis with or without the presence of DM. DM was defined as any tumor recurrence outside the pelvis with or without the presence of LR. We examined the role of the following clinical and pathologic factors: age, sex, race, tumor size, tumor mobility, circumferential extent of tumor, obstructive symptoms, distance from anal verge, anal canal involvement, clinical T and N stages, pathologic T and N stages, pathology, histologic grade, lymphovascular invasion, perineural involvement, and radial margin. Wald tests were performed to identify significant univariate predictors of LR, DM, and OS. Wald test was also performed to investigate whether radiation dose was associated with LR. Cox proportional hazards regression analysis was then performed to identify significant multivariate predictors of local and distant failure and OS. All univariate significant variables were entered into a multivariate model, except variables with missing values for more than 25% of cases. In a backward stepwise fashion, the univariate significant variable with the least significance was eliminated from the multivariate model. This was continued until only significant variables remained. A P value less than 0.05 was considered significant.
RESULTS

Relapses and Survival
Forty-two (9%) patients had LR and 100 (21%) patients had DM, of which 9 had simultaneous local and distant failures and 14 had sequential local and distant failures. The estimated 5-year rate of freedom from LR was 90%, and the estimated 5-year rate of freedom from DM was 79%. There were 131 deaths from any cause, including 80 deaths from rectal cancer, 30 deaths from other causes and 21 deaths from unknown causes. The estimated 5-year OS rate was 80%.
Univariate Predictors
Significant univariate predictors of LR were female sex, clinical T stage, positive radial margin, and pathologic T and N stages (Table 3 ). Significant univariate predictors of DM were circumferential extent of tumor, tumor immobility, lymphovascular invasion, perineural involvement, and pathologic T and N stages. Significant univariate predictors of lower OS were age, circumferential extent of tumor, shorter distance from anal verge, tumor size, tumor immobility, anal canal involvement, lymphovascular invasion, perineural in- volvement, positive radial margin, and pathologic T and N stages.
Multivariate Predictors
Cox proportional hazards analysis showed that female sex, and pathologic T and N stages independently predicted for LR (Table 4) . Moreover, pathologic T and N stages were independent predictors of DM. Cox proportional hazards analysis also showed that age, circumferential extent of tumor, positive radial margin, and pathologic T and N stages independently predicted for lower OS. The estimated rates of local control, distant control, and OS, stratified by pathologic T and N stages, and pathologic stage groups are shown in Table 5 . The estimated 5-year OS rate was 89% for pathologic T stage Յ2 but decreased to 68% for T3 and 63% for T4. The estimated 5-year OS was 84% for pathologic nodenegative and 69% for pathologic node-positive patients. The Kaplan-Meier curves for OS, stratified by pathologic T and N stages, are shown in Figures 1 and 2 .
DISCUSSION
We performed this large single-institution retrospective study to identify predictive factors for LR, DM, and OS in patients with rectal cancer. While various clinical and pathologic factors predicted for these end points, pathologic T and N stages significantly predicted for all 3 end points LR, DM, and OS on multivariate analysis. Our findings complement those of other recent studies. A pooled analysis of 5 randomized rectal cancer trials with 3,791 patients showed that the rates of LR, DM, disease-free survival and OS were dependent on the pathologic T and N stages. 5 Furthermore, the N substage within the separate T stages, and the T substage within the separate N stages, were associated with OS, disease-free survival, local recurrence, and DM. 5 Prognostic factors were also evaluated in the German intergroup trial comparing preoperative and postoperative chemoradiation. 8 Among the 406 patients in the preoperative chemoradiation arm, pathologic T stage, pathologic N stage, grade, lymphatic invasion, and tumor regression grade significantly predicted for disease-free survival on univariate analysis. On multivariate analysis, pathologic N stage significantly predicted for local relapse-free survival, and pathologic T and N stages significantly predicted for disease-free survival and metastasis-free survival. A retrospective study on 218 patients treated with preoperative radiotherapy in France showed that age, sex, and pathologic T and N stages were associated with OS. 9 Taken together, these studies indicate that pathologic T and N stages are key determinants of survival and relapse in rectal cancer patients.
A better understanding of predictive factors will help in the design of risk-adapted therapy for rectal cancer patients. Currently, there is no consensus about whether all rectal cancer patients require adjuvant chemotherapy in addition to concurrent chemoradiation. A meta-analysis on colon cancer patients indicated that only patients with node-positive colon cancer and selected patients with node-negative colon cancer benefit from adjuvant chemotherapy. 10 The recently reported EORTC 22921 trial evaluated the role of adjuvant chemotherapy in rectal cancer patients. 11 In a 2 ϫ 2 factorial randomization, patients who had received preoperative radiation with or without chemotherapy were randomized to receive either 4 cycles of 5-FU and leucovorin or no further therapy after surgery. Patients who received adjuvant chemotherapy had a greater 5-year OS rate than those receiving no adjuvant chemotherapy after surgery (67% versus 63%), but this difference did not reach statistical significance (P ϭ 0.12). 11 In this trial, patients were not stratified for prognostic factors such as pathologic T or N stage. 11 Perhaps stratification on the basis of T and N stages in future trials will help to identify high-risk subgroups that would benefit from adjuvant chemotherapy. Certain subgroups of rectal cancer patients may need no adjuvant chemotherapy, and some may require the current standard of fluoropyrimidine-based chemotherapy, while some may benefit from more aggressive chemotherapy regimens. Our study suggests that pathologic T and N stages can help guide therapy in these patients. At our institution, we currently recommend adjuvant FOLFOX (5-FU, leucovorin, and oxaliplatin) for high-risk patients, and adjuvant 5-FU/leucovorin or capecitabine for low-risk patients.
Predictive factors can also help in the design of trials investigating new agents. In recent years, randomized trials in colorectal cancer patients have proven the role of a number of chemotherapeutic and biologic agents, such as oxaliplatin for adjuvant treatment of colon cancers and bevacizumab and cetuximab for treatment of metastatic colorectal cancers. [12] [13] [14] The next generation of trials for rectal cancers needs to investigate the role of such agents in the neoadjuvant and adjuvant therapy for rectal cancers. The findings of this study indicate that patients with pathologic stage T3 or T4 disease and those with positive nodes have the highest risk of relapse and death, and should therefore be targeted in future adjuvant and neoadjuvant trials.
In addition to pathologic T and N stages, certain other factors were significant predictors on multivariate analysis. Female sex independently predicted for LR. Females may potentially have a higher risk of locoregional failure from vaginal or uterine involvement. Age, circumferential extent of tumor and positive radial margin independently predicted for OS, but not LR or DM. Such factors may also be valuable in making treatment decisions and designing future trials. Multiple previous studies have identified radial margin status as an important predictive factor in rectal cancer. 15, 16 This retrospective study has certain limitations. The study was based on hospital records, and pathology review was not performed for the study. Pathologic information was not available on certain potential predictors, such as tumor distance from the radial margin. A large majority of the patients received preoperative radiation therapy, which has been shown to decrease nodal retrieval, potentially affecting nodal staging. 17 Information about some predictors, such as lymphovascular invasion and perineural invasion, was not available for all patients. Because the study included patients treated preoperatively as well as those treated postoperatively, we were not able to analyze whether response to therapy or tumor downstaging had a predictive role. Prior studies from our institution reported that response to preoperative chemoradiation was associated with improved disease-free and OS. 18, 19 In future studies, we plan to further delineate predictive factors in the subpopulation of patients treated with preoperative chemoradiation.
In summary, pathologic T and N stages independently predicted for LR, DM, and OS in rectal cancer patients treated with mesorectal excision and chemoradiation. These findings imply that trials of more aggressive adjuvant chemotherapy agents are warranted for rectal cancer patients with pathologic stage T3/T4 or node-positive disease.
